Mydecine Innovations Group, Inc. (TSE:MYCO) has released an update.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mydecine Innovations Group Inc. has announced a restatement of its 2022 financials due to a valuation error regarding its share transactions and an overlooked asset security agreement. The correction will affect the company’s cash position, increasing debt and expenses. The revised financial statements will be filed later than originally scheduled, replacing the previous inaccurate documents.
For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.